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Abstract 
A specific and sensitive radioimmunoassay for human adrenomedullin has been developed and distribution and characterization of immunoreactive 
adrenomedullin in human tissue were investigated. The radioimmunoassay specifically recognizes its carboxyterminal region and half maximal 
inhibition of binding of radioiodinated adrenomedullin(40-52)NH2 was observed at 11 fmol/tube. Immunoreactive adrenomedullin was abundant 
in adrenal medulla (47.7 f 26.1 fmollmg, mean f S.D.) and was ubiquitously found in all tissue examined. The mean plasma concentration of 
adrenomedullin i  three normal individuals was 17.2 f 6.4 pg/ml (mean f S.D.). By analysis with reverse-phase high-performance liquid chromatog- 
raphy coupled with the radioimmunoassay, most immunoreactive adrenomedullin in the adrenal medulla, atrium and lung was found to be 
adrenomedullin( l152)NHz 
Key words: Adrenomedullin; Specific radioimmunoassay; Distribution; Characterization 
1. Introduction 
Adrenomedullin (AM) is a potent hypotensive peptide 
which has been recently identified in extracts of human 
pheochromocytoma (PC) tissue by monitoring its elevat- 
ing activity on rat platelet CAMP. AM, consisting of 52 
amino acid residues, has a C-terminal tyrosine amide 
structure and one intramolecular disulfide bond, and 
shares slight homology with calcitonin gene-related pep- 
tide (CGRP) and amylin [l]. The hypotensive activity of 
AM is comparable to that of CGRP which has been 
established as one of the strongest vasorelaxants [2]. 
In our former study, we developed a radioimmunoas- 
say (RIA) for AM(3-12), which is generated from AM 
and its precursor by trypsin digestion. However, this 
RIA could not recognize AM( l-52)NH, without trypsin 
digestion. AM was found to be abundant in human adre- 
nal medulla as well as in PC [l], while high levels of AM 
mRNA were found in lung, ventricle and kidney as well 
as in adrenal medulla and PC [3]. To elucidate the bio- 
synthesis of AM in several tissues and to investigate the 
possible biological role of AM, it is essential to develop 
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an assay system to detect AM. In the present study, we 
have established a specific and sensitive RIA for human 
AM and have determined the distribution and molecular 
form of AM in human tissue and plasma. 
2. Materials and methods 
2.1. Peptides 
Adrenomedullin(4&52), (45552), (47752)NH, and (45552)CDOH 
were synthesized by the solid phase method with a peptide synthesizer 
(430A, Applied Biosystems), and purified by reverse-phase high-per- 
formance liquid chromatography (HPLC). Human synthetic adre- 
nomedullin prepared by solid phase methods in the Peptide Institute, 
Inc. (Osaka, Japan), will be described elsewhere. 
2.2. Preparation of antiserum 
Human AM(4&52)NH, (10 mg) was conjugated with bovine thy- 
roglobulin (20 mg) by the carbodiimide method [4]. The reaction mix- 
ture was dialyzed four times against one liter of 0.9% NaCl and two 
times against one liter of 0.05 M sodium phosphate buffer (pH 7.4), 
containing 0.08 M NaCl. The antigenic onjugate solution (1.5-3 ml) 
was emulsified with an equal volume of Freund’s complete adjuvant, 
and was used for immunizing New Zealand white rabbits by subcutane- 
ous injection. Animals received booster injections every two weeks and 
were bled 7 days after each injection. 
2.3. Radioiodination of ligand 
N-succinimidyl 3-(4-hydroxy,5-(‘251)iodophenyl)propionate was pur- 
chased from Amersham, Inc. (Tokyo, Japan). Human AM(40-52)NH, 
was radioiodinated by the Bolton and Hunter method [S]. The ‘*‘I- 
labeled peptide was purified by reverse-phase HPLC on a TSK ODS 
120A column. 
2 4. Procedures for RIA 
RIA for adrenomedullin was performed by a method similar to that 
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reported for C-type natriuretic peptide [6]. Incubation buffer for RIA 
for adrenomedullin was 0.05 M sodium phosphate buffer (pH 7.4), 
containing 1% bovine serum albumin (BSA), 0.5% Triton X-100, 0.08 
M NaCl, 0.025 M EDTA-2Na and 0.05% NaN,. The RIA incubation 
mixture consisted of 100 ~1 of either the standard or the sample solu- 
tion, 50 ~1 of antiserum at a dilution of 1:182,250 and 50 ,~l of “‘I- 
labeled ligand (18,000 cpm) in the standard buffer. The above mixture 
was placed in a plastic tube (7.5 x 78 mm), mixed well, and then equili- 
brated at 4°C for 24 h. The incubation was stopped by adding 50 ~1 
of 1% bovine g-globulin and 500 ~1 of 24% polyethyleneglycol(#6,000) 
in the standard buffer. After vigorous shaking, the mixture was incu- 
bated at 4°C for 20 min and centrifuged at 2,000 x g at 4’C for 30 min. 
The supernatant was aspirated, and radioactivity in the pellets was 
counted in a gamma counter. Assays were routinely performed in dupli- 
cate. 
2.5. Preparation of peptide extract 
Peptide extract was prepared by a method similar to that previously 
described [7,8]. Human tissues were obtained from cadavers and human 
pheochromocytoma tissues were resected at surgery from three nore- 
pinephrine dominant pheochromocytoma patients. Diced pieces of ad- 
renal medulla and pheochromocytoma tissues were boiled for 10 min 
in 3 vol. of 1 M acetic acid. Those of the other tissues were boiled for 
10 min in 3 vol. of H,O to inactivate intrinsic proteases. After cooling, 
glacial acetic acid was added to a final concentration of 1 M. The 
mixture was homogenized with a polytron mixer at 4°C. The extract 
supematant was obtained after 30 min centrifugation at 24,000 x g. The 
supematant from each tissue was loaded to a Sep-Pak C-18 cartridge 
(Waters, Inc., Massachusetts, USA) pre-equilibrated with 0.5 M acetic 
acid. Adsorbed materials were eluted with 3 ml of 60% acetonitrile in 
0.1% trifluoroacetic acid (TFA). The eluates were evaporated in vac- 
uum to dryness. Residual materials were dissolved in RlA buffer and 
the clear solution submitted to RIA. 
3. Results and discussion 
3.1. RIA for AM 
The antiserum against AM was raised by injection of 
synthetic human AM(40-52)NH, conjugated with thy- 
roglobulin. Antiserum designated # 172CI-9 recognized 
human AM(4&52)NH, with high affinity at a final dilu- 
tion of 729,000. As seen in Fig. 1, half-maximal inhibi- 
Table 1 
Regional distribution and plasma concentration of immunoreactive 
adrenomedullin in human 
Region Immunoreactive adrenomedullin 
Adrenal medulla 47.7 f 26.1 
Pheochromocytoma 92.1 f 101.6 
Heart Atrium 1.68 f 1.58 
Heart Ventricle 0.15 f 0.02 
Aorta 0.42 + 0.09 
Lung 0.80 + 0.37 
Kidney 0.35 f 0.12 
Pancreas 1.04& 0.35 
Small intestine 0.97 + 0.45 
Liver 0.20 + 0.06 
Spleen 0.53 + 0.10 
Brain cortex 0.31 +_ 0.15 
Thyroid gland 0.28 f 0.12 
Plasma* 17.2 f 6.4 
Results are expressed as fmol/mg wet tissue. 
*Plasma concentration of AM is expressed as pg/ml. All values are 
mean f S.D. for three to four samples. 
0.25 0.5 1.0 
1 10 100 
fmol/tube 
1000 
Fig. 1. Standard curve of radioimmunoassay for adrenomedullin and 
cross-reactivity of antiserum #171CI-9. Inhibition of ‘*‘I-labeled 
AM(4&52)NH, binding to the antiserum by serial dilutions of 
AM(l-52)NH2, (45-52)NH,, (47-52)NH, (o), (45-52)COOH (A), 
CGRPs (m), amylin (m) and NPY (m). AM(45-52)COOH showed 2.5% 
cross-reactivity with the antiserum. The latter three were derived from 
human and none exhibited any cross-reactivity with the antiserum. 
Inhibition of ‘251-labeled AM(4&52)NH, binding to the antiserum by 
serial dilutions of human adrenal medulla sample (0). is roughly paral- 
lel to that of standard AM(l-52)NHz. 
tion by AM(4&52)NH, and human AM was observed 
at 11 fmolkube, and the peptide was detectable as low 
as 1 fmolkube. The intra- and inter-assay coefficients of 
variance were less than 6% and 9%, respectively. The 
dilution curve of extracts of human adrenal medulla was 
parallel to the standard curve. Human AM, AM(45- 
52)NH, and AM(47-52)NHz showed 100% cross-reac- 
tivity with the antiserum, but human AM(45-52)COOH 
showed only 2.5% cross-reactivity. In addition, lz51- 
Tyr5*AM(40-52)NH, radioiodinated by the lactoperoxi- 
dase method [9] was poorly recognized by antiserum 
#172CI-9. Therefore, antiserum #172CI-9 specifically 
recognized mainly the C-terminal tyrosine amide struc- 
ture of AM. These results indicate that this RIA may be 
useful for detection of biological active AM, because of 
the importance of the C-terminal amide structure in 
many biologically active peptides [lo]. Although AM 
shares slight homology with CGRP or amylin, the anti- 
serum did not exhibit cross-reactivity with human 
CGRP- I, II and amylin. Neuropeptide Y (NPY) also has 
a C-terminal tyrosine amide structure, but the present 
RIA showed no cross-reactivity with NPY. 
3.2. Distribution of ir-adrenomedullin human tissue 
Tissue AM contents are summarized in Table 1. High 
concentrations of immunoreactive (ir-) AM were present 
in adrenal medulla (47.7 k 26.1 fmoYmg wet tissue, 
mean k SD.), confirming our previous results [l]. Fur- 
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Fig. 2. Reverse-phase HPLC of human tissue extract monitored by RIA 
for AM. Sample: (a) adrenal medulla (2 mg es.), (b) atrium (80 mg eq.), 
(c) lung (150 mg es.). Column: TSK ODS 120A (4.6 x 150 mm, Tosoh). 
Flow rate: 1 ml/min. Solvent system: (A) H,O/CH,CN/lO% TFA = 
9O:lO:l (by volume), (B) HzO/CH,CN/lO% TFA = 40:60:1 (by volume). 
Linear gradient from (A) to (B) for 60 min. The arrow indicates elution 
position of AM. 
thermore, ir-AM was also detected in atrium, lung, pan- 
creas and small intestine in relatively high concentrations 
and was found in smaller amounts in brain and ventricle. 
The concentration of ir-AM in ventricle, kidney and lung 
was less than 3% of that in adrenal medulla, while high 
levels of AM mRNA were found in ventricle, kidney and 
lung as well as in adrenal medulla [3]. This discrepancy 
may be explained by the possibility that AM which is 
biosynthesized in these tissues may be rapidly released 
into the blood or metabolized in each tissue. Although 
ir-AM was detected in pancreas and small intestine, very 
slight AM mRNA expression was detected in pancreas 
and intestine [3], suggesting that biosynthetic systems 
and excretion may be different in each tissue. In addition, 
it is interesting that ir-AM concentration in atrium was 
more than IO-fold that in ventricle. Even though the 
physiological implication of AM in atrium is obscure, it 
may be involved in circulatory control in a similar man- 
ner to that of CGRP and ANP which were found to be 
abundant in atrium [ 11,121. 
PC ir-AM concentration was 92.1 ? 101.6 fmol/mg 
wet weight (mean ? SD.), which is the highest concen- 
tration among all tissues examined. Although ir-AM 
concentration of PC varied in each case, PC may be a 
tumor that produces AM as well as catecholamine. 
The mean plasma concentration of AM in three nor- 
mal individuals ranged from 12.2 to 24.4 pg/ml with a 
mean of 17.3 & 6.4 (mean ? SD.) pg/ml. 
3.3. Characterization of k-AA4 in adrenal gland, atrium, 
lung and plasma 
The ir-AM in adrenal gland, atrium and lung was 
further characterized by reverse-phase HPLC using a 
TSK ODS 120A column coupled with RIA for AM. As 
shown in Fig. 2, one major peak and several minor peaks 
of ir-AM were observed in adrenal gland, atrium and 
lung. The major peak emerged at an identical elution 
time with authentic AM( l-52)NH,. Furthermore, by gel 
filtration HPLC on a TSK-Gel2OOOSW column (Tosoh, 
Inc. Japan) coupled with RIA for AM, in adrenal me- 
dulla the major ir-AM peak emerged at an identical elu- 
tion time with authentic AM as shown in Fig. 3. The 
minor ir-AM peak which emerged in the lower molecular 
weight range is considered to be C-terminal fragments of 
cd e 
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Ftg. 3. Gel filtration HPLC of human adrenal medulla extract mom- 
tored by RIA for AM. Sample: adrenal medulla (10 mg eq.) Column: 
TSK-Gel 2000SW (8.0 x 500 mm, Tosoh). Eluent: 30% CH,CN solu- 
tion containing 0.1% TFA and 0.2 M NaCI. Flow rate: 0.5 ml/min. 
Arrows Indicate elutron positions of (a) Vo. (b) cytochrome c. (c) AM, 
(d) CGRP-I, (e) insulin chain B, respectively. 
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AM, as antiserum #172CI-9 recognized mainly the C- 
terminal tyrosine amide structure of AM. Although the 
major ir-AM peak was found to be AM itself, several 
minor peaks were observed in each of the three different 
tissues examined, the identification of which is now 
under way. 
I 
jOd 
By gel filtration of human plasma coupled with RIA 
for AM, two major ir-AM peaks were observed as shown 
in Fig. 4. The first ir-AM peak, which constituted about 
50% of the total ir-AM, emerged at an identical elution 
time with authentic AM. The second peak emerged in the 
lower molecular weight range. Two peaks were further 
characterized by reverse-phase HPLC coupled with RIA 
for AM. The first ir-AM peak in the gel filtration of 
plasma was eluted at an identical position with authentic 
AM and the second ir-AM peak was eluted at an earlier 
position (Fig. 5). These results indicate that ir-AM in 
human plasma consisted of AM itself and its C-terminal 
fragment whose biological activity remains obscure. 
, 
I,_ 
In conclusion, we have established a new specific and 
sensitive RIA for AM which recognizes the C-terminal 
tyrosine amide structure of AM. High concentrations of 
ir-AM were found in adrenal medulla and PC, where 
AM was originally discovered. In addition, ir-AM was 
found in all human tissues examined, indicating that AM 
a) 
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Fig. 4. Gel filtration of human plasma monitored by RIA for AM. 
Sample: human plasma (100 ml). Column: Sephadex G-50 (1.5 x 100 
cm). Eluent: 1 N acetate. Flow rate: 12 ml/h. Arrows indicate elution 
positions of (a) Vo, (b) AM, (c) aprotinin. (d) Vt, respectively. 
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Fig. 5. Reverse-phase HPLC of two major peaks in Fig. 4 monitored 
by RIA for AM. Sample: (a) first major peak, (b) second major peak 
in Fig. 4. Column: TSK ODS 120A (4.6 x 150 mm, Tosoh). Flow rate: 
1 ml/min. Solvent system: (A) H,O/CH,CN/lO% TFA = 9O:lO:l (by 
volume), (B) H20/CH,CN/10% TFA = 40:60:1 (by volume). Linear 
gradient from (A) to (B) for 60 min. The arrow indicates elution posi- 
tion of AM. 
is ubiquitously distributed in human tissue and may be 
involved in circulatory control in these organs. Measure- 
ment of the plasma concentration of AM could help to 
clarify the pathophysiological significance of AM in a 
variety of diseases. 
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